Dassault Systemes eyes life science boost with $5.7B Medidata buy

New York City
New York-based biopharma services company Medidata Solutions will help boost Dassault Systemes' life science ambitions. (Pixabay)

Clinical trial specialist Medidata Solutions is being bought out by France’s Dassault Systemes in a $5.7 billion deal designed to help the tech firm diversify deeper into the biopharma services world.

The cash deal sees the New York-based company subsumed into Dassault, which has specialized in design software but now wants in on the lucrative CRO and clinical trial space that has seen a bunch of high-end deals and buyouts in recent years.

“This is by far the largest acquisition we’ve ever made,” Pascal Daloz, chief financial officer of Dassault, said on a conference call and quoted in Fortune.

Webinar

De-risking the Development of Biotherapeutics Using Early Stage In Vitro Expression and Genetic Characterisation Tools

There is a high attrition rate during the development of biotherapeutics impacting the high cost of development. Early identification of the preferred expression host for manufacturing, along with lead candidate screening and material supply can help to reduce both attrition rates and cost.

Medidata, which had sales of $636 million last year, has been making its own deals over the years, including pacts with biotechs such as Forty Seven. In 2017, it inked a deal centered on site payments for Worldwide Clinical Trials after the biopharma services company spent 18 months looking for the right partner.

Last summer, Big Pharma giant Novartis also penned a deal with Shyft, a Medidata subsidiary, to help strengthen its digital solutions and help it push on with the launch of new therapies targeted for the European market.

Back in 2016 it also made its own buyout, snapping up Intelemage and integrating its medical image sharing technology into its cloud-based clinical trial platform.

Suggested Articles

California is halting its expansion, citing costs, despite seeing record-setting spikes in new infections and increases in hospitalizations.

Antivirals from Roche, Bristol Myers Squibb, Viiv and Gilead, or modified versions of them, could prove effective against COVID-19, researchers said.

The Canadian devicemaker Kardium has received European approval for its spherical heart ablation system designed to treat atrial fibrillation.